Enables A2A adenosine receptor binding activity; glutamate receptor activity; and protein tyrosine kinase binding activity. Involved in several processes, including G protein-coupled receptor signaling pathway; regulation of signal transduction; and trans-synaptic signaling. Located in astrocyte projection; dendrite; and postsynaptic density membrane. Is active in glutamatergic synapse and postsynaptic membrane. Orthologous to human GRM5 (glutamate metabotropic receptor 5); PARTICIPATES IN calcium/calcium-mediated signaling pathway; glutamate signaling pathway; Huntington's disease pathway; INTERACTS WITH (+)-pilocarpine; (S)-3,5-dihydroxyphenylglycine; (S)-amphetamine.
[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] which results in decreased susceptibility to Pilocarpine
6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein, FMR1 gene mutant form promotes the reaction [6-methyl-2-(phenylethynyl)pyridine binds to GRM5 protein]
Dactinomycin inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 mRNA], Dactinomycin inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 protein]
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GRM5 protein
Amphetamine promotes the reaction [[2-chloro-5-hydroxyphenylglycine binds to and results in increased activity of GRM5 protein] which results in increased hydrolysis of Phosphatidylinositols], GRM5 protein promotes the reaction [Amphetamine results in increased expression of FOS mRNA]
Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 mRNA], Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 protein]
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GRM5 protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GRM5 protein
[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in decreased abundance of Dopamine] more ...
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GRM5 protein
[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in decreased abundance of Dopamine], [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]
[3-cyano-N-(1, 3-diphenyl-1H-pyrazol-5-yl)benzamide binds to GRM5 protein] promotes the reaction [Quisqualic Acid binds to and results in increased activity of GRM5 protein]
[3-cyano-N-(1, 3-diphenyl-1H-pyrazol-5-yl)benzamide binds to GRM5 protein] promotes the reaction [Quisqualic Acid binds to and results in increased activity of GRM5 protein]
Sodium Fluoride promotes the reaction [sodium arsenite results in decreased expression of GRM5 mRNA], Sodium Fluoride promotes the reaction [sodium arsenite results in decreased expression of GRM5 protein]
Sodium Fluoride promotes the reaction [sodium arsenite results in decreased expression of GRM5 mRNA], Sodium Fluoride promotes the reaction [sodium arsenite results in decreased expression of GRM5 protein]
[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Veratridine results in increased secretion of Dopamine]
Co-localization of caldesmon and calponin with cortical afferents, metabotropic glutamate and neurotrophic receptors in the lateral and central nuclei of the amygdala.
Metabotropic glutamate receptor 5 (mGluR5)-mediated phosphoinositide hydrolysis and NMDA-potentiating effects are blunted in the striatum of aged rats: a possible additional mechanism in striatal senescence.
Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites.
The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
Dissociation of protein kinase-mediated regulation of metabotropic glutamate receptor 7 (mGluR7) interactions with calmodulin and regulation of mGluR7 function.
acts synergistically with the adenosine A2a-receptor (Adora2a) to increase c-fos expression in striatal sections, counteracting phencyclidine-induced motor activation
